Purpose of application and links to ... - Department of Health
Public Summary DocumentApplication No. 1313– Bone mineral density analyses using Dual Energy X-ray Absorptiometry (DXA) in breast cancer patients receiving aromatase inhibitor treatmentApplicant:Australian and New Zealand Bone Mineral SocietyDate of MSAC consideration:MSAC 64th Meeting, 30-31 July 2015Context for decision: MSAC makes its advice in accordance with its Terms of Reference, see at .auPurpose of application and links to other applicationsAn application requesting MBS listing of bone densitometry dual energy X-ray absorptiometry (DXA) for post-menopausal women with early stage breast cancer who receive, or are being considered for, treatment with aromatase inhibitors, was received from the Australian and New Zealand Bone and Mineral Society (ANZBMS). MSAC deferred the application in November 2014 and requested further external evaluation of the economic modelling. The evidence for assessment of this application was submitted in May 2015.MSAC’s advice to the MinisterAfter considering the available evidence presented in relation to safety, clinical effectiveness and cost-effectiveness of bone densitometry dual energy X-ray absorptiometry (DXA), MSAC did not support public funding because of uncertain and unacceptably high cost-effectiveness in the proposed setting.Summary of consideration and rationale for MSAC’s adviceMSAC recalled that the previous application was deferred to seek further external evaluation of the economic modelling, especially of the estimates of elevated fracture risks and prescription drug costs.MSAC noted there were no studies presented of the analytical or clinical validity of DXA in women taking aromatase inhibitors, and so these needed to be extrapolated from other studies of DXA. The results for the updated data indicated that DXA scanning and anti-resorptive therapy in women receiving aromatase inhibitor treatment is superior to placebo for BMD loss in the lumbar spine and hip and may be effective at reducing the relative risk of fractures (but with a high level of unexplained between study heterogeneity). MSAC noted that there were fewer bone fractures in women taking aromatase inhibitors who also took anti-resorptives than in women taking aromatase inhibitors who did not take anti-resorptives, the difference in rate of fracture was not statistically significant. However, MSAC considered that the claimed superiority was biologically plausible, particularly as there is no clinical reason why anti-resorptives would work differently in patients taking aromatase inhibitors.MSAC noted that the cost estimates used in this application assume that the target population can access PBS-subsidised anti-resorptives, however this would require an application to the PBAC for at least one of these medicines in order to broaden the current eligibility criteria to include women who meet the proposed criteria to start anti-resorptive treatment.MSAC considered that most of the amended model inputs to the economic model were reasonable but expressed concern with the limited clinical benefit. MSAC noted that the ICERs were considerably less favourable than generated by the versions of the model considered previously. MSAC expressed concern with the large difference in the ICER for the base case scenario, which was approximately $47,000 when only women (aged 60 years) with osteoporosis on aromatase inhibitors were included, compared to when women with osteopenia were also included and the ICER increased to over $250,000. MSAC also noted that the ICER increased in the younger population (aged 50 years) and decreased for the older population (aged 65 years). Overall, MSAC judged that use of DXA scanning in the population of women over 50 years with osteopenia or osteoporosis that are taking aromatase inhibitors was not acceptably cost-effective. MSAC considered that it would be impractical in this context to attempt to limit the use of non-subsidised anti-resorptives to osteoporosis and not osteopenia.BackgroundAt the November 2014 meeting, MSAC deferred the application to seek further external evaluation of the economic modelling, especially of the estimates of elevated fracture risks and prescription drug costs. MSAC separately supported amending the current MBS items for BMD analysis to allow trained technicians to perform DXA scanning under the supervision of a medical practitioner. MSAC considered that this should also involve a fee review of these parative safetyIn November 2014, MSAC noted that there were no studies that assessed the safety of DXA scans in the population of interest. However, DXA in general, is a widely used technique that is considered to be safe, being non-invasive, and using low levels of radiation, the equivalent of two to four days of background parative effectivenessInformation of DXA performanceDXA came into practice in 1987 and has since been recognised as the gold standard of BMD measurement. It has very low radiation doses, high image resolution, precision and stable calibration of the instruments. With supporting data on normal BMD ranges for different population groups, DXA allows for an immediate diagnosis of whether a person has osteopenia or osteoporosis.The Assessment Report identified seven studies which assessed the effectiveness of DXA in predicting fractures compared with fracture risk tools. The performance of DXA is also determined by manufacturer quality control factors. Analytical performance of BMD is influenced by device, operator performance, and physiological composition, therefore good quality control of the DXA device and use is important ADDIN EN.CITE <EndNote><Cite><Author>Homik</Author><Year>1999</Year><RecNum>235</RecNum><DisplayText>(Homik and Hailey 1999)</DisplayText><record><rec-number>235</rec-number><foreign-keys><key app="EN" db-id="v9edw0zeqvve5nedzvjx29f1df2z2tvpvw55" timestamp="1398311956">235</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author>Homik, J.</author><author>Hailey, D.</author></authors></contributors><titles><title>Selective testing with bone density measurement (Structured abstract)</title><secondary-title>Health Technology Assessment Database</secondary-title></titles><periodical><full-title>Health Technology Assessment Database</full-title></periodical><number>1</number><keywords><keyword>Absorptiometry, Photon</keyword><keyword>Bone Density</keyword><keyword>Mass Screening</keyword><keyword>Osteoporosis</keyword></keywords><dates><year>1999</year></dates><publisher>Alberta Heritage Foundation for Medical Research (AHFMR)</publisher><accession-num>HTA-31999009317</accession-num><label>Included</label><urls><related-urls><url>;(Homik and Hailey 1999).Methods to assess treatment effects on change in BMDA systematic review of fourteen studies was undertaken on the efficacy of treatments for aromatase-inhibitor-associated bone loss.Although there were several systematic reviews and meta-analyses on anti-resorptive bone treatment efficacy in women taking aromatase-inhibitors PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5IYWRqaTwvQXV0aG9yPjxZZWFyPjIwMTE8L1llYXI+PFJl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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5IYWRqaTwvQXV0aG9yPjxZZWFyPjIwMTE8L1llYXI+PFJl
Y051bT41MzwvUmVjTnVtPjxEaXNwbGF5VGV4dD4oUGVyZXogYW5kIFdlaWxiYWVjaGVyIDIwMDYs
IEhhZGppLCBBYXBybyBldCBhbC4gMjAxMSk8L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+PHJlYy1udW1i
ZXI+NTM8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJ2OWVk
dzB6ZXF2dmU1bmVkenZqeDI5ZjFkZjJ6MnR2cHZ3NTUiIHRpbWVzdGFtcD0iMTM5Njg0MTM2NSI+
NTM8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4x
NzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPkhhZGppLCBQLjwvYXV0
aG9yPjxhdXRob3I+QWFwcm8sIE0uIFMuPC9hdXRob3I+PGF1dGhvcj5Cb2R5LCBKLiBKLjwvYXV0
aG9yPjxhdXRob3I+QnVuZHJlZCwgTi4gSi48L2F1dGhvcj48YXV0aG9yPkJydWZza3ksIEEuPC9h
dXRob3I+PGF1dGhvcj5Db2xlbWFuLCBSLiBFLjwvYXV0aG9yPjxhdXRob3I+R25hbnQsIE0uPC9h
dXRob3I+PGF1dGhvcj5HdWlzZSwgVC48L2F1dGhvcj48YXV0aG9yPkxpcHRvbiwgQS48L2F1dGhv
cj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5EZXBhcnRtZW50IG9mIEVu
ZG9jcmlub2xvZ3ksIFBoaWxpcHBzLVVuaXZlcnNpdHkgb2YgTWFyYnVyZywgR2VybWFueS4gaGFk
amlAbWVkLnVuaS1tYXJidXJnLmRlPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+TWFuYWdl
bWVudCBvZiBhcm9tYXRhc2UgaW5oaWJpdG9yLWFzc29jaWF0ZWQgYm9uZSBsb3NzIGluIHBvc3Rt
ZW5vcGF1c2FsIHdvbWVuIHdpdGggYnJlYXN0IGNhbmNlcjogcHJhY3RpY2FsIGd1aWRhbmNlIGZv
ciBwcmV2ZW50aW9uIGFuZCB0cmVhdG1lbnQ8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+QW5uYWxz
IG9mIE9uY29sb2d5PC9zZWNvbmRhcnktdGl0bGU+PGFsdC10aXRsZT5Bbm4gT25jb2w8L2FsdC10
aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5Bbm5hbHMgb2YgT25jb2xvZ3k8
L2Z1bGwtdGl0bGU+PGFiYnItMT5Bbm4gT25jb2w8L2FiYnItMT48L3BlcmlvZGljYWw+PGFsdC1w
ZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkFubmFscyBvZiBPbmNvbG9neTwvZnVsbC10aXRsZT48YWJi
ci0xPkFubiBPbmNvbDwvYWJici0xPjwvYWx0LXBlcmlvZGljYWw+PHBhZ2VzPjI1NDYtNTU8L3Bh
Z2VzPjx2b2x1bWU+MjI8L3ZvbHVtZT48bnVtYmVyPjEyPC9udW1iZXI+PGtleXdvcmRzPjxrZXl3
b3JkPipBbnRpbmVvcGxhc3RpYyBBZ2VudHMvYWUgW0FkdmVyc2UgRWZmZWN0c108L2tleXdvcmQ+
PGtleXdvcmQ+QW50aW5lb3BsYXN0aWMgQWdlbnRzL3R1IFtUaGVyYXBldXRpYyBVc2VdPC9rZXl3
b3JkPjxrZXl3b3JkPipBcm9tYXRhc2UgSW5oaWJpdG9ycy9hZSBbQWR2ZXJzZSBFZmZlY3RzXTwv
a2V5d29yZD48a2V5d29yZD5Bcm9tYXRhc2UgSW5oaWJpdG9ycy90dSBbVGhlcmFwZXV0aWMgVXNl
XTwva2V5d29yZD48a2V5d29yZD4qQm9uZSBEZW5zaXR5IENvbnNlcnZhdGlvbiBBZ2VudHMvdHUg
W1RoZXJhcGV1dGljIFVzZV08L2tleXdvcmQ+PGtleXdvcmQ+KkJyZWFzdCBOZW9wbGFzbXMvZHQg
W0RydWcgVGhlcmFweV08L2tleXdvcmQ+PGtleXdvcmQ+KkRpcGhvc3Bob25hdGVzL3R1IFtUaGVy
YXBldXRpYyBVc2VdPC9rZXl3b3JkPjxrZXl3b3JkPkZlbWFsZTwva2V5d29yZD48a2V5d29yZD5I
dW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+SW1pZGF6b2xlczwva2V5d29yZD48a2V5d29yZD4qT3N0
ZW9wb3Jvc2lzLCBQb3N0bWVub3BhdXNhbC9jaSBbQ2hlbWljYWxseSBJbmR1Y2VkXTwva2V5d29y
ZD48a2V5d29yZD5Pc3Rlb3Bvcm9zaXMsIFBvc3RtZW5vcGF1c2FsL3BjIFtQcmV2ZW50aW9uICZh
bXA7IENvbnRyb2xdPC9rZXl3b3JkPjxrZXl3b3JkPlByYWN0aWNlIEd1aWRlbGluZXMgYXMgVG9w
aWM8L2tleXdvcmQ+PGtleXdvcmQ+UmFuZG9taXplZCBDb250cm9sbGVkIFRyaWFscyBhcyBUb3Bp
Yzwva2V5d29yZD48a2V5d29yZD5SaXNrIEZhY3RvcnM8L2tleXdvcmQ+PGtleXdvcmQ+MCAoQW50
aW5lb3BsYXN0aWMgQWdlbnRzKTwva2V5d29yZD48a2V5d29yZD4wIChBcm9tYXRhc2UgSW5oaWJp
dG9ycyk8L2tleXdvcmQ+PGtleXdvcmQ+MCAoQm9uZSBEZW5zaXR5IENvbnNlcnZhdGlvbiBBZ2Vu
dHMpPC9rZXl3b3JkPjxrZXl3b3JkPjAgKERpcGhvc3Bob25hdGVzKTwva2V5d29yZD48a2V5d29y
ZD4wIChJbWlkYXpvbGVzKTwva2V5d29yZD48a2V5d29yZD4xMTgwNzItOTMtOCAoem9sZWRyb25p
YyBhY2lkKTwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDExPC95ZWFyPjxwdWIt
ZGF0ZXM+PGRhdGU+RGVjPC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTU2OS04MDQx
PC9pc2JuPjxhY2Nlc3Npb24tbnVtPjIxNDE1MjMzPC9hY2Nlc3Npb24tbnVtPjx3b3JrLXR5cGU+
UmVzZWFyY2ggU3VwcG9ydCwgTm9uLVUuUy4gR292JmFwb3M7dCYjeEQ7UmV2aWV3PC93b3JrLXR5
cGU+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHA6Ly9vdmlkc3Aub3ZpZC5jb20vb3ZpZHdl
Yi5jZ2k/VD1KUyZhbXA7Q1NDPVkmYW1wO05FV1M9TiZhbXA7UEFHRT1mdWxsdGV4dCZhbXA7RD1t
ZWRsJmFtcDtBTj0yMTQxNTIzMzwvdXJsPjx1cmw+aHR0cDovL2h5OGZ5OWpqNGIuc2VhcmNoLnNl
cmlhbHNzb2x1dGlvbnMuY29tLyA/dXJsX3Zlcj1aMzkuODgtMjAwNCZhbXA7cmZ0X3ZhbF9mbXQ9
aW5mbzpvZmkvZm10OmtldjptdHg6am91cm5hbCZhbXA7cmZyX2lkPWluZm86c2lkL092aWQ6bWVk
bCZhbXA7cmZ0LmdlbnJlPWFydGljbGUmYW1wO3JmdF9pZD1pbmZvOmRvaS8xMC4xMDkzJTJGYW5u
b25jJTJGbWRyMDE3JmFtcDtyZnRfaWQ9aW5mbzpwbWlkLzIxNDE1MjMzJmFtcDtyZnQuaXNzbj0w
OTIzLTc1MzQmYW1wO3JmdC52b2x1bWU9MjImYW1wO3JmdC5pc3N1ZT0xMiZhbXA7cmZ0LnNwYWdl
PTI1NDYmYW1wO3JmdC5wYWdlcz0yNTQ2LTU1JmFtcDtyZnQuZGF0ZT0yMDExJmFtcDtyZnQuanRp
dGxlPUFubmFscytvZitPbmNvbG9neSZhbXA7cmZ0LmF0aXRsZT1NYW5hZ2VtZW50K29mK2Fyb21h
dGFzZStpbmhpYml0b3ItYXNzb2NpYXRlZCtib25lK2xvc3MraW4rcG9zdG1lbm9wYXVzYWwrd29t
ZW4rd2l0aCticmVhc3QrY2FuY2VyJTNBK3ByYWN0aWNhbCtndWlkYW5jZStmb3IrcHJldmVudGlv
bithbmQrdHJlYXRtZW50LiZhbXA7cmZ0LmF1bGFzdD1IYWRqaTwvdXJsPjwvcmVsYXRlZC11cmxz
PjwvdXJscz48ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5
My9hbm5vbmMvbWRyMDE3PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48cmVtb3RlLWRhdGFiYXNl
LW5hbWU+TUVETElORTwvcmVtb3RlLWRhdGFiYXNlLW5hbWU+PHJlbW90ZS1kYXRhYmFzZS1wcm92
aWRlcj5PdmlkIFRlY2hub2xvZ2llczwvcmVtb3RlLWRhdGFiYXNlLXByb3ZpZGVyPjxsYW5ndWFn
ZT5FbmdsaXNoPC9sYW5ndWFnZT48L3JlY29yZD48L0NpdGU+PENpdGU+PEF1dGhvcj5QZXJlejwv
QXV0aG9yPjxZZWFyPjIwMDY8L1llYXI+PFJlY051bT45NTwvUmVjTnVtPjxyZWNvcmQ+PHJlYy1u
dW1iZXI+OTU8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJ2
OWVkdzB6ZXF2dmU1bmVkenZqeDI5ZjFkZjJ6MnR2cHZ3NTUiIHRpbWVzdGFtcD0iMTM5Njg0MTM2
NiI+OTU8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xl
Ij4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPlBlcmV6LCBFLiBB
LjwvYXV0aG9yPjxhdXRob3I+V2VpbGJhZWNoZXIsIEsuPC9hdXRob3I+PC9hdXRob3JzPjwvY29u
dHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+RGl2aXNvbiBvZiBIZW1hdG9sb2d5L09uY29sb2d5LCBN
YXlvIENsaW5pYywgSmFja3NvbnZpbGxlLCBGbG9yaWRhIDMyMjI0LCBVU0EuIHBlcmV6LmVkaXRo
QG1heW8uZWR1PC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+QXJvbWF0YXNlIGluaGliaXRv
cnMgYW5kIGJvbmUgbG9zczwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5PbmNvbG9neSAoV2lsbGlz
dG9uIFBhcmspPC9zZWNvbmRhcnktdGl0bGU+PGFsdC10aXRsZT5PbmNvbG9neSAoV2lsbGlzdG9u
KTwvYWx0LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPk9uY29sb2d5IChX
aWxsaXN0b24gUGFyayk8L2Z1bGwtdGl0bGU+PGFiYnItMT5PbmNvbG9neSAoV2lsbGlzdG9uKTwv
YWJici0xPjwvcGVyaW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+T25jb2xvZ3kg
KFdpbGxpc3RvbiBQYXJrKTwvZnVsbC10aXRsZT48YWJici0xPk9uY29sb2d5IChXaWxsaXN0b24p
PC9hYmJyLTE+PC9hbHQtcGVyaW9kaWNhbD48cGFnZXM+MTAyOS0zOTsgZGlzY3Vzc2lvbiAxMDM5
LTQwLCAxMDQyLCAxMDQ4PC9wYWdlcz48dm9sdW1lPjIwPC92b2x1bWU+PG51bWJlcj45PC9udW1i
ZXI+PGtleXdvcmRzPjxrZXl3b3JkPipBcm9tYXRhc2UgSW5oaWJpdG9ycy9hZSBbQWR2ZXJzZSBF
ZmZlY3RzXTwva2V5d29yZD48a2V5d29yZD4qQm9uZSBEZW5zaXR5IENvbnNlcnZhdGlvbiBBZ2Vu
dHMvdHUgW1RoZXJhcGV1dGljIFVzZV08L2tleXdvcmQ+PGtleXdvcmQ+Qm9uZSBSZXNvcnB0aW9u
L2NpIFtDaGVtaWNhbGx5IEluZHVjZWRdPC9rZXl3b3JkPjxrZXl3b3JkPipCb25lIFJlc29ycHRp
b24vZHQgW0RydWcgVGhlcmFweV08L2tleXdvcmQ+PGtleXdvcmQ+QnJlYXN0IE5lb3BsYXNtcy9j
byBbQ29tcGxpY2F0aW9uc108L2tleXdvcmQ+PGtleXdvcmQ+KkJyZWFzdCBOZW9wbGFzbXMvZHQg
W0RydWcgVGhlcmFweV08L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3Jk
Pkh1bWFuczwva2V5d29yZD48a2V5d29yZD4wIChBcm9tYXRhc2UgSW5oaWJpdG9ycyk8L2tleXdv
cmQ+PGtleXdvcmQ+MCAoQm9uZSBEZW5zaXR5IENvbnNlcnZhdGlvbiBBZ2VudHMpPC9rZXl3b3Jk
Pjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMDY8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5BdWc8
L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4wODkwLTkwOTE8L2lzYm4+PGFjY2Vzc2lv
bi1udW0+MTY5ODYzNDg8L2FjY2Vzc2lvbi1udW0+PHdvcmstdHlwZT5SZXZpZXc8L3dvcmstdHlw
ZT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL292aWRzcC5vdmlkLmNvbS9vdmlkd2Vi
LmNnaT9UPUpTJmFtcDtDU0M9WSZhbXA7TkVXUz1OJmFtcDtQQUdFPWZ1bGx0ZXh0JmFtcDtEPW1l
ZDUmYW1wO0FOPTE2OTg2MzQ4PC91cmw+PHVybD5odHRwOi8vaHk4Znk5amo0Yi5zZWFyY2guc2Vy
aWFsc3NvbHV0aW9ucy5jb20vID91cmxfdmVyPVozOS44OC0yMDA0JmFtcDtyZnRfdmFsX2ZtdD1p
bmZvOm9maS9mbXQ6a2V2Om10eDpqb3VybmFsJmFtcDtyZnJfaWQ9aW5mbzpzaWQvT3ZpZDptZWQ1
JmFtcDtyZnQuZ2VucmU9YXJ0aWNsZSZhbXA7cmZ0X2lkPWluZm86ZG9pLyZhbXA7cmZ0X2lkPWlu
Zm86cG1pZC8xNjk4NjM0OCZhbXA7cmZ0Lmlzc249MDg5MC05MDkxJmFtcDtyZnQudm9sdW1lPTIw
JmFtcDtyZnQuaXNzdWU9OSZhbXA7cmZ0LnNwYWdlPTEwMjkmYW1wO3JmdC5wYWdlcz0xMDI5LTM5
JTNCK2Rpc2N1c3Npb24rMTAzOS00MCUyQysxMDQyJTJDKzEwNDgmYW1wO3JmdC5kYXRlPTIwMDYm
YW1wO3JmdC5qdGl0bGU9T25jb2xvZ3krJTI4V2lsbGlzdG9uK1BhcmslMjkmYW1wO3JmdC5hdGl0
bGU9QXJvbWF0YXNlK2luaGliaXRvcnMrYW5kK2JvbmUrbG9zcy4mYW1wO3JmdC5hdWxhc3Q9UGVy
ZXo8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGN1c3RvbTI+TklITVM5NDEzOSYjeEQ7UE1D
MjY5Mzg5NjwvY3VzdG9tMj48cmVtb3RlLWRhdGFiYXNlLW5hbWU+TUVETElORTwvcmVtb3RlLWRh
dGFiYXNlLW5hbWU+PHJlbW90ZS1kYXRhYmFzZS1wcm92aWRlcj5PdmlkIFRlY2hub2xvZ2llczwv
cmVtb3RlLWRhdGFiYXNlLXByb3ZpZGVyPjxsYW5ndWFnZT5FbmdsaXNoPC9sYW5ndWFnZT48L3Jl
Y29yZD48L0NpdGU+PC9FbmROb3RlPgAAAA==
ADDIN EN.CITE.DATA (Perez and Weilbaecher 2006, Hadji, Aapro et al. 2011), they included many studies that have been superseded by more recent reports of outcomes from longer follow-ups. With updated data, the findings were presented both descriptively, using bar graphs and summary table, and statistically using a random-effects meta-analysis. The key treatment outcome in the main trials was percentage change in BMD of the lumbar spine and hip. Negative BMD change values indicate bone density loss while a positive BMD change indicate the favourable outcome of bone density gain.The percentage change in BMD results are summarised graphically below.Figure 1: % change in BMD lumbar spine of studies on treatments for AI-associated bone lossNB: Control group for Bruksky, Coleman, Llombart, Hines and Takahashi was ‘delayed zoledronic acid’ not placebo. Figure 2: % change in BMD total hip of studies on treatments for AI-associated bone lossNB: Control group for Bruksky, Coleman, Llombart, Hines and Takahashi wais ‘delayed zoledronic acid’ not placebo. A meta-analysis was performed using a random effects model. Where BMD was recorded for different follow-up times, the BMD of the longest follow-up period was included. Study heterogeneity was assessed using the I2 statistic where >50-74% was considered moderate heterogeneity and ≥75% was considered high heterogeneity. Analyses were undertaken for BMD lumbar spine and total hip outcomes. Subgroup analyses were undertaken, by early or longer follow up period (≤ or > 24 months) and by zoledronic acid versus other bone treatment.Interpretation of results of change in BMDThe presentation of the trial results for ‘percentage change in BMD’ was in terms of standardised mean difference. For BMD lumbar spine, the standardised mean difference between the intervention and comparator arms were 1.46% and for BMD total hip was 1.48%.The revised meta-analyses present the results of the mean difference across treatment arms in percentage change in BMD over time in Tables 1 and 2, consistent with the bar graphs in the Assessment Report.Table 1: Mean difference in treatment arms in percentage change in BMD (hip) by studyFigure 3: Forest plot of mean difference in % change in BMD (total hip) Favours comparatorFavours treatmentTable 2: Mean difference in treatment arms in percentage change in BMD (lumbar spine) by studyFigure 4: Forest plot of mean % change in BMD (lumbar spine)Favours comparatorFavours treatmentThe findings of the meta-analysis show a pooled effect of 5.6% difference across groups in the change in BMD (95%CI: 3.5% to 7.7%) at the hip and 5.8% (95%CI: 4.1% to 7.4%) at the lumbar spine. The pooled findings show positive bone density and are consistent and significant. Based on updated data, they indicate a superior benefit of anti-resorptive therapy for women with breast cancer on aromatase inhibitors for increasing bone density compared with no treatment.However, study heterogeneity was problematic and high as indicated by I2 ≥90.0%. No study dominated these results as they equally contributed to the final results (between 9-12%) (Tables 1 and 2). The three key studies with the largest sample sizes and five-year follow-ups, Brufsky 2012, Coleman 2013 and Llombart 2012, produced consistent results.Balance of benefits and harms for BMD managementThe intervention proposed in the application, DXA and anti-resorptive treatment, as shown by the evidence in this assessment, is superior to placebo for BMD loss in the lumbar spine and hip and may be superior in terms of bone fractures. Although fewer bone fractures were observed in the trials in women taking AR, the numbers were low and a lack of statistical power was the likely reason for a lack of statistical significance.Table 3 below summarises the comparative benefits and harms for ‘DXA plus anti-resorptives’ compared with placebo, based on the trials identified in the systematic review.The common adverse events reported by women in the AI trials on anti-resorptive treatments were arthralgia, hot flushes, fatigue, myalgia, bone pain and fever. Arthralgia, fever, hot flushes and fatigue are also common symptoms for AI treatment making the attribution of them to AI or AR therapy blurred.Table 3: Summary of comparative benefits and harms for DXA plus ARs and PBO* Median duration of follow-up; 5 years (Brufsky 2012, Coleman 2013, Llombart 2012, Safra 2011), 24 months (Hines), 12 months (Takahashi 2012, Nuzzo 2012)Abbreviations: PBO = placebo; RD = risk difference; RR = risk ratioSource: Compiled during the evaluationZoledronic acid was the only anti-resorptive used in the studies reporting harms in Table 3. With women on AR therapy, there were a significantly higher proportion of women experiencing bone pain and fever in the studies. There appeared to be a protective effect of hot flushes in two studies PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5MbG9tYmFydDwvQXV0aG9yPjxZZWFyPjIwMTI8L1llYXI+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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5MbG9tYmFydDwvQXV0aG9yPjxZZWFyPjIwMTI8L1llYXI+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ADDIN EN.CITE.DATA (Safra, Bernstein-Molho et al. 2011, Llombart, Frassoldati et al. 2012). Also fatigue was found in one study PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5IaW5lczwvQXV0aG9yPjxZZWFyPjIwMDk8L1llYXI+PFJl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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5IaW5lczwvQXV0aG9yPjxZZWFyPjIwMDk8L1llYXI+PFJl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ADDIN EN.CITE.DATA (Hines, Mincey et al. 2009). Not all studies reported all types of adverse events or only reported them selectively.Due to the higher occurrence of bone pain and fever in patients and fever that would likely be managed by over-the-counter medication, these additional resources were considered in the financial estimates for consumers. They were not included in the economic model as they would not likely to impact over a 40-year duration.Economic evaluationA summary of the revisions in the economic model are provided in Table 4 below.Table 4: Changes to inputs for the revised economic modelConcernCurrent model estimatesRevised model estimatesDXA frequencyAnnualBaseline, 24 months, 48 monthsRR of fx due to osteoporosis3.75, sensitivity analysis: 3.5 and 4.03.75, sensitivity analysis: 2.0 and 5.0RR of fx due to AR therapy0.66, sensitivity analysis: 0.40 and 0.850.701, sensitivity analysis: 0.40 and 0.85Cost of fxHip fx $17,515 (±30% $12258, $22766)Spine fx $11,974 (±30% $8381, $15566)Other fx $2,416 (±30% $1691, $3141)Taking a wider account of costs and allowing for inpatient and outpatient scenarios:Hip fx $23,695 (±30% $16,586, $30,803)Spine fx $5,753 (±30% $4,027, $7,479)Other fx $9,158 (±30% $6,411, $11,905)Survival of women on AR QALYs onlyLife years saved added as an outcomeAR therapy adherence100% adherence40.5% adherence2 (applied in model through RR of fx while on AR allowing for non-adherence)RR of fx while on AR allowing for non-adherenceNot applicable RR of fx 1.20 (1.07, 1.35)2AR price allowing for non-adherence$619.80 per year$428.28 per year (modified by non-adherence)Cost of zoledronic acid treatment$1252 per year$589 per yearCorrection to probability of fracture in modelModel originally had fractures underestimated and not cycling through the fracture risk tables correctly.Corrected.AR = Anti-resorptive, DXA = dual absorptiometry X-ray, fx = fracture, RR = relative risk, QALYs = quality adjusted life years Based on a meta-analysis during evaluation.Based on Modi 2015 where the non-adherence rate was 59.5%, or adherence 40.5% ADDIN EN.CITE <EndNote><Cite><Author>Modi</Author><Year>2015</Year><RecNum>304</RecNum><DisplayText>(Modi, Siris et al. 2015)</DisplayText><record><rec-number>304</rec-number><foreign-keys><key app="EN" db-id="v9edw0zeqvve5nedzvjx29f1df2z2tvpvw55" timestamp="1430698963">304</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Modi, A.</author><author>Siris, E. S.</author><author>Tang, J.</author><author>Sen, S.</author></authors></contributors><auth-address>Merck & Co. Inc. , Lebanon, NJ , USA.</auth-address><titles><title>Cost and consequences of noncompliance with osteoporosis treatment among women initiating therapy</title><secondary-title>Curr Med Res Opin</secondary-title><alt-title>Current medical research and opinion</alt-title></titles><periodical><full-title>Current Medical Research & Opinion</full-title><abbr-1>Curr Med Res Opin</abbr-1></periodical><pages>757-65</pages><volume>31</volume><number>4</number><edition>2015/02/11</edition><dates><year>2015</year><pub-dates><date>Apr</date></pub-dates></dates><isbn>0300-7995</isbn><accession-num>25661017</accession-num><urls></urls><electronic-resource-num>10.1185/03007995.2015.1016605</electronic-resource-num><remote-database-provider>Nlm</remote-database-provider><language>eng</language></record></Cite></EndNote>(Modi, Siris et al. 2015).The model was revised and the updated results are provided below in Tables 5 and 6. Table 5 presents the outcomes for a 60 year old cohort over their remaining lifetime and costs and effects discounted at 5%. The results for the subgroup of DXA and AR for all women with breast cancer on AI therapy (i.e., regardless of T-score) is not shown as this subgroup is unlikely to be realistic in clinical practice. The costs are in 2014 Australian dollars.Table 5: Key results of economic evaluation 60 year old cohort, discountedMean CostsMean QALYsInc CostsInc QALYsICER Previous base case-----No DXA and lifestyle advice only (all women)$4,05611.657refrefrefDXA + ARtx (osteoporosis)$5,33111.956$1,2750.299$4,264DXA + ARtx (osteoporosis + osteopenia)$10,24911.959$6,1930.302$20,507Revised base case-----No DXA and lifestyle advice only (all women)$7,54511.822refrefrefDXA + ARtx (osteoporosis)$7,97311.831$4280.009$47,556DXA + ARtx (osteoporosis + osteopenia)$10,58111.834$3,0360.012$253,000ARtx = Anti-resorptive therapy, DXA = dual absorptiometry X-ray, ICER = incremental cost effectiveness ratio, inc = incremental, QALYs = quality adjusted life years Over their remaining lives, for a cohort of 60 year old women with breast cancer taking AIs, the mean cost for DXA plus AR therapy for osteoporosis was estimated at $7,973 compared with $7,545 for risk assessment plus lifestyle advice. The corresponding mean QALYs were 11.831 and 11.822, respectively. Consequently, the incremental cost per QALY ratio, for women with osteoporosis, was $47,556 per QALY gained. The ICER was considerably higher for women receiving DXA plus AR therapy with osteoporosis or osteopenia where the mean costs drove up the ICER to $253,000.The results for fractures and life years saved are presented in Table 6. The costs and effects are undiscounted. Fractures are expressed as per 1000 women.Table 6: Results of economic evaluation (60 year old cohort, undiscounted, life years saved and fractures)InterventionMean CostsMean EffectsInc CostsInc EffectsICER--LYS-LYSLYSNo DXA and lifestyle advice only (all women)$21,06225.593refrefrefDXA + ARtx (osteoporosis)$21,44925.626$3870.033$11,727DXA + ARtx (osteoporosis + osteopenia)$25,81125.632$4,7490.039$121,769--Fx per 1000-Fx avoidedICERFx avoidedNo DXA and lifestyle advice only (all women)$21,062887refrefrefDXA + ARtx (osteoporosis)$21,449831$38756$6,911DXA + ARtx (osteoporosis + osteopenia)$25,811810$4,74977$61,675ARtx = Anti-resorptive therapy, DXA = dual absorptiometry X-ray, fx = fracture, ICER = incremental cost effectiveness ratio, LYS = life years saved, QALYs = quality adjusted life years The predicted additional survival was 12-14 days for women in the two DXA and AR therapy treatment groups. The small survival gain is most likely due to women in all three groups having similar outcomes as they age, irrespective of the short-lived benefits of the reduced fracture risk during the five years of AI treatment when women are 60 years old at the start. The number of fractures avoided was 56-77 over the 40 year model duration.Sensitivity analyses were completed for different starting age cohorts; 50 and 65 year old women and presented in Table 7.Table 7: Results of economic model by starting age cohortsType of sensitivity analysisCostsQALYsInc CostsInc QALYsICER60 year olds (base case)-----No DXA and lifestyle advice$7,54511.822refrefrefDXA and ARtx (osteoporosis)$7,97311.831$4280.009$47,556DXA and ARtx (osteoporosis and osteopenia)$10,58111.834$3,0360.012$253,00050 year olds-----No DXA and lifestyle advice$5,09813.648refrefrefDXA and ARtx (osteoporosis)$5,79713.654$6990.006$116,500DXA and ARtx (osteoporosis and osteopenia)$8,99113.656$3,8930.008$486,62565 year olds-----No DXA and lifestyle advice$7,61610.679refrefrefDXA and ARtx (osteoporosis)$8,00910.689$3930.010$39,300DXA and ARtx (osteoporosis and osteopenia)$10,37010.693$2,7540.014$196,714ARtx = Anti-resorptive therapy, DXA = dual absorptiometry X-ray, ICER = incremental cost effectiveness ratio, QALYs = quality adjusted life yearsThe model predicted that interventions confined to 50 year old women with breast cancer on AI therapy would not be cost effective (ICERs >$116,000) due to the lack of benefit arising. In older women aged 65 years, the interventions were more cost-effective due to lower incremental costs and QALYs proportionally. In no age group was the intervention cost-effective in the larger group of women with osteoporosis or osteopenia.One-way sensitivity analyses were conducted for all other variables in the model. The most influential inputs are presented in Table 8.Table 8: One-way sensitivity analysis for incremental cost per QALY (discounted)ParameterRange testedICER ($/QALY) DXA + AR Osteoporosis(T-score≤-2.5)ICER ($/QALY) DXA + AR Osteoporosisor osteopenia(T-score≤-1.0)Base case-$47,556$253,000Probability of osteoporosis at start0.089 - 0.21-$1068, $155,358$177,356, $334,789Weighted RR of fracture in all women1.57 to 1.80$16,409, $147,892$161,529, $433,450RR of a fracture in osteoporosis2.0-5.0$11,898, $76,326$241,289, $241,289Discount rate for effects0.0 - 0.07$12,621, $74,531$74,161, $373,184RR of excess death from 1st fracture2.52 - 3.27$41,424, $93,528$218,414, $472,116RR of fracture in aromatase inhibitors therapy with AR0.4 - 0.85$14,188, $64,428$52,680, $117,1183Cost of AR therapy$428 – $626$45,913, $80,780$241,289, $373,073Fracture risk adjustment factor for non-adherence with AR treatment1.07 - 1.35$36,971, $56,854$152,960, $499,737Background utility for early stage breast cancer0.728 - 0.986$41,094, $52,013$217,006, $271,689RR of excess death from 2nd fracture1.74 - 2.92$40,758, $50,803$214,480, $266,659Probability of a 2nd fracture 0.57 - 0.92$41,270, $50,465$220,775, $261,528Cost of a hip fracture$16,586-$30,803$41,613, $49,725$236,356, $245,661Cost of spine fracture$4,027-$7,479$43,856, $47,152$238,854, $242,755Discount rate for costs0.07 - 0.0$41,478, $44,040$208,076, $377,391AR = Anti-resorptive therapy, DXA = dual absorptiometry X-ray, ICER = incremental cost effectiveness ratio, QALYs = quality adjusted life years; RR = relative riskBolded = 5 most influential variables for broader group.These one-way sensitivity findings show that the model is relatively unstable to changes in the above variables. The ICER moves below or above $50,000 per QALY with variation to the estimates. The most important drivers of the model were the probability of women with osteoporosis, the relative risk of fracture for all women, relative risk of fracture in osteoporosis discount rate of QALYs, relative risk of fracture in AI and AR and the non-adherence of AR (via reduced bone treatment effect).A probabilistic sensitivity analysis was undertaken using 5000 simulations. This provides the likelihood of the model having cost-effective results below the cost per QALY threshold of $50,000. The results of these analyses are provided in Table 9.Table 9: Results of the probabilistic sensitivity analysisType of Sensitivity Analysis% cost-effective (<$50,000 per QALY gain)No DXA and lifestyle advicerefDXA and ARtx (osteoporosis)50.8%DXA and ARtx (osteoporosis and osteopenia)6.0%AR = Anti-resorptive therapy, DXA = dual absorptiometry X-ray, QALYs = quality adjusted life yearsThe outcome of the above analysis suggests that in about half of the interventions, the intervention of DXA plus AR therapy for women with osteoporosis is cost-effective when a threshold of $50,000 per QALY is used. It would not be a cost-effective intervention for a broader group of women who had either osteoporosis or osteopenia.Model validationThe model was assessed for internal and external validity.To assess the reliability of the model outputs, the predicted survival and number of fractures were compared with those from other Australian sources. These are summarised in Table 10. The type of model, the starting age and source for the relative fracture risk estimate were the same (Table 10).Table 10: Comparison of outcomes from our model with external studies Parameter External evidenceEconomic model predictionsSurvivalABS Life Tables: 60 year old women life expectancy is 26.4 years or age 86.4 years.Mean survival (LYS) = 25.593-25.632 years or age 85.6 yearsSurvivalAIHW Cancer in Australia Women with early-stage breast cancer 5-year survival rate 97%Adjustment in the model was made for early-stage breast cancer survival and would contribute to the lower mean survival above. Incidence of fracturesLifetime risk of osteoporotic fractures >50 years : 440 to 560 cases per 1000 womenTasmanian Older Adult Cohort = 44%Geelong Osteoporosis Study = 42%Dubbo Study = 56%Source: ADDIN EN.CITE <EndNote><Cite><Author>Watts</Author><Year>2013</Year><RecNum>303</RecNum><DisplayText>(Watts, Abimanyi-Ochom et al. 2013)</DisplayText><record><rec-number>303</rec-number><foreign-keys><key app="EN" db-id="v9edw0zeqvve5nedzvjx29f1df2z2tvpvw55" timestamp="1430698629">303</key></foreign-keys><ref-type name="Report">27</ref-type><contributors><authors><author>Watts, J.J.</author><author>Abimanyi-Ochom, J.</author><author>Sanders, K.M.</author></authors></contributors><titles><title>Osteoporosis costing all Australians: A new burden of disease analysis 2012 to 2022.</title></titles><dates><year>2013</year></dates><pub-location>Sydney</pub-location><publisher>Osteoporosis Australia.</publisher><urls></urls></record></Cite></EndNote>(Watts, Abimanyi-Ochom et al. 2013)810 to 887 fractures per 1000 women. Although this seems high in the economic model, the model includes women experiencing second fractures which are a large proportion (73%) PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5LYW5pczwvQXV0aG9yPjxZZWFyPjIwMDQ8L1llYXI+PFJl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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5LYW5pczwvQXV0aG9yPjxZZWFyPjIwMDQ8L1llYXI+PFJl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ADDIN EN.CITE.DATA (Kanis, Johnell et al. 2004).Incidence of fracturesFractures during AR therapy, observational US data >32,000 women, 50% osteoporosisFractures: % women with first fracture at 12 months ranged 1.2% to 1.5%, therefore 1.5% x 1000 x 40 years = 600 fractures expected per 1000 women.Source: PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TaWx2ZXJtYW48L0F1dGhvcj48WWVhcj4yMDA3PC9ZZWFy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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TaWx2ZXJtYW48L0F1dGhvcj48WWVhcj4yMDA3PC9ZZWFy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ADDIN EN.CITE.DATA (Silverman, Watts et al. 2007)As above. Includes first fractures only.Although this is not Australian, it is a prospective observational study including women from all backgrounds.ABS = Australian Bureau of Statistics; AIHW = Australian Institute of Health and Welfare; LYS = life years savedThe economic model predicted reasonably close estimates of numbers of fractures and survival as expected when compared with other sources.External validity of the revised model was assessed by comparing the model features and outcomes to those from existing cost-effectiveness studies from other countries.Overall, the results from the applicant’s model seem to be reasonably close for the group of women with osteoporosis but somewhat outside the other findings for the larger group with osteoporosis or osteopenia. The incremental QALYs in the applicant’s model were similar compared with the UK and US study findings. The incremental costs appear similar across all three studies. The model findings were closest to the values from the UK report with ICERs of ?16,069 to ?24,868 per QALY PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Mb2dtYW48L0F1dGhvcj48WWVhcj4yMDEwPC9ZZWFyPjxS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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Mb2dtYW48L0F1dGhvcj48WWVhcj4yMDEwPC9ZZWFyPjxS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ADDIN EN.CITE.DATA (Logman, Heeg et al. 2010). The number of fractures averted predicted from the applicant’s model, 53-73 per 1,000 patients appear to be at the high end of the UK study.Financial/budgetary impactsCurrent pricing issues of anti-resorptive therapiesThe bone anti-resorptive medications available on the PBS for osteoporosis are available to persons if they have osteoporosis as defined by a T-score ≤-2.5 and they are at least 70 years old. In women diagnosed with breast cancer in Australia, 64% are aged between 45-69 years and on average are diagnosed at age 60 ADDIN EN.CITE <EndNote><Cite><Author>Australian Institute of Health and Welfare</Author><Year>2014</Year><RecNum>299</RecNum><DisplayText>(Australian Institute of Health and Welfare 2014)</DisplayText><record><rec-number>299</rec-number><foreign-keys><key app="EN" db-id="v9edw0zeqvve5nedzvjx29f1df2z2tvpvw55" timestamp="1414635836">299</key></foreign-keys><ref-type name="Report">27</ref-type><contributors><authors><author>Australian Institute of Health and Welfare,</author></authors></contributors><titles><title>Australian Cancer Incidence and Mortality (ACIM) book for breast cancer</title></titles><volume>Incidence table</volume><dates><year>2014</year></dates><pub-location>Canberra</pub-location><publisher>AIHW</publisher><urls><related-urls><url>;(Australian Institute of Health and Welfare 2014). Therefore, anti-resorptives for two-thirds of the target group are not currently available for PBS subsidy and would currently need to be prescribed outside the PBS and paid for by the patient.If a sponsor applied for broader eligibility criteria to women of earlier ages or specifically aligned with the population proposed in this application, the pricing would apply as detailed further below. The financial estimates therefore assume that risedronate is available through the PBS to the target population of this application.Frequency of DXA scansAnnual DXA scan frequency was the base case in the Assessment Report. This was because annual scans matched the proposed MBS item description for the target population where it is worded as ‘no more than every 12 months’, which aligns with current practice guidelines and appears to be current practice for a proportion of women with breast cancer in Australia according to the feedback from the Breast Cancer Network Australia. Two-yearly scans were tested in sensitivity analyses. The Australian and New Zealand Bone and Mineral Society (ANZBMS) has said there is no consensus on the frequency of scans in the target population.At the request of ESC and MSAC, both the economic model and financial estimates have been revised to include an initial scan in the first year and follow up scans at Years 3 and 5.Eligibility for DXA scans via existing MBS items and for PBS therapiesFor existing MBS items for DXA scans, the most applicable items that could apply to the target group are items relating to persons with comorbid conditions; 12306, 12309, 12312, 12315, and 12318 (Box 1). All these items have the same scheduled fee $102.40 and this is also the nominated fee for the proposed MBS item. Assessing any replacement of one MBS DXA item for the proposed MBS item would therefore mean a cost-neutral effect on the financial assessment. Therefore, no adjustments in the financial estimates were made for this issue.The number of women with early-stage breast cancer and taking AI therapy with the concurrent conditions listed in Box 1 is unknown. The MBS item 12312 for DXA BMD is available for women with premature menopause before the age of 45 years with one service only in a period of 12 months. This may apply to women where premature menopause is an adverse event of chemotherapy treatment and possibly other adjuvant treatments for breast cancer. It is estimated up to 50% of women younger than 40 years would develop permanent premature menopause. However, this would represent a small number of women each year diagnosed with breast cancer (approximately 767 x 50% = 384) and not all of these would have early-stage disease.Box 1. Eligibility for DXA items on MBS where concurrent conditions applyFor Items 12306 and 12309 the referral should specify the indication for the test, namely:(a)1 or more fractures occurring after minimal trauma; or(b)monitoring of low bone mineral density proven by previous bone densitometry.?For Item 12312 the referral should specify the indication for the test, namely:(a)prolonged glucocorticoid therapy;(b)conditions associated with excess glucocorticoid secretion;(c)male hypogonadism; or(d)female hypogonadism lasting more than 6 months before the age of 45.?For Item 12315 the referral should specify the indication for the test, namely:(a)primary hyperparathyroidism;(b)chronic liver disease;(c)chronic renal disease;(d)proven malabsorptive disorders;(e)rheumatoid arthritis; or(f)conditions associated with thyroxine excess.?For Item 12318 the referral should specify the indication for the test, namely:(a)prolonged glucocorticoid therapy;(b)conditions associated with excess glucocorticoid secretion;(c)male hypogonadism;(d)female hypogonadism lasting more than 6 months before the age of 45;(e)primary hyperparathyroidism;(f)chronic liver disease;(g)chronic renal disease;(h)proven malabsorptive disorders;(i)rheumatoid arthritis; or(j)conditions associated with thyroxine excess.Costs to the MBS for general practitioner visitsThe applicant’s financial estimates have been revised to include two standard GP visits (item 23), originally there was only one GP visit added.Co-payment for risedronate and safety net considerationsBased on the prescriptions for aromatase inhibitors medications on the PBS for the previous 12 months, letrozole, anastrazole and exemestane, the total number of scripts were $486,604. The financial estimates were modified to account for the PBS and patient co-payment disbursements above.Adherence to risedronateThe adherence rate of risedronate was revised down according to Modi 2015 reflecting osteoporotic medication in the general post-menopausal women population, 40.5% were adherent. This was assumed to be constant for five years.Revised financial estimatesThe financial estimates were updated to include the revised estimates above. Also, the cost of fractures avoided used a weighted cost $14,855 based on updated fracture costs.The PBS costs assume access to anti-resorptives by the target population. Currently this is not the case and an alternative approach is to view PBS costs as zero and view these as paid by consumers in full.The results of the revised calculations are provided in Table 11.Table 11: Results of the financial estimates over the next five yearsEligible populationYear 1Year 2Year 3Year 4Year 5Incidence of women with brca aged 50-6981088293847986658851Proportion with early stage72977464763177987966Proportion taking aromatase inhibitors59116046618163176452Total number of women each year591111956181382445430906Estimated uptake of DXA scansYear 1Year 2Year 3Year 4Year 5Number of scans if at baseline, then at 24 and 48 mths59116046120921236318544Estimated women taking anti-resorptivesYear 1Year 2Year 3Year 4Year 5Proportion of women with osteoporosis8661752265735834528Total women treated8661752265735834528MBS Costs Year 1Year 2Year 3Year 4Year 5DXA scans $514,510 $1,040,770 $1,578,913 $2,128,721 $2,690,367 Vitamin D tests $150,969 $154,427 $157,886 $161,344 $164,802 GP visits $429,103 $868,036 $1,316,798 $1,775,389 $2,243,810 PBS Costs of anti-resorptives (risedronate 8749Y)Year 1Year 2Year 3Year 4Year 5 General ordinary patients 36% $29,551 $59,779 $90,684 $122,266 $154,525 General safety net patients 2% $8,209 $16,605 $25,190 $33,963 $42,924 Concessional ordinary 50% $205,216 $415,133 $629,750 $849,069 $1,073,088 Concessional free safety net 12% $56,858 $115,018 $174,481 $235,246 $297,313 Compliance rate of anti-resorptive40.5%40.5%40.5%40.5%40.5%Total cost of anti-resorptives $121,433 $245,647 $372,643 $502,420 $634,979 Hospital cost savings from fracture preventionYear 1Year 2Year 3Year 4Year 5Expected incidence of fractures (all women on AI)85172261352445Number of women untreated (no osteoporosis)504510205154812087226379Number of fractures in untreated women73147223301380Number of fractures in treated women918273646Fractures prevented48111520Cost of fractures avoided (weighted mean AR-DRG)$14,855 $14,855$14,855$14,855$14,855Total cost savings - $55,567 - $112,406 - $170,518 - $229,903 - $290,561 TOTAL MBS COSTS$1,094,583$1,548,759$2,527,275$3,012,896$4,022,857TOTAL PBS COSTS$121,433$245,647$372,643$502,420$634,979TOTAL STATE GOVT COST SAVINGS-$55,567-$112,406-$170,518-$229,903-$290,561TOTAL COSTS$1,160,449$1,682,000$2,729,400$3,285,413$4,367,275AI = aromatase inhibitor, AR-DRG = Australian Related Diagnosis Relative Group, brca = breast cancer, DXA = dual x-ray absorptiometry, GP = general practitioner, MBS = Medical Benefits Schedule, PBS= Pharmaceutical Benefits Schedule.The costs estimated in Table 11 are for women with osteoporosis. The results increase when the patient group is extended for women with osteoporosis or osteopenia; five-year totals are MBS costs $12,206,371, PBS costs $8,168,360, state government cost savings $3,737,758, overall total $16,636,973.The financial estimates for patients are in Table 12. The cost for bone pain and fever as an adverse event of anti-resorptive therapies was based on over-the-counter consumer purchase of paracetamol (48 tablets 500mg) at a cost of $2.70 per patient (.au). This cost was applied once only for all new patients in each year.Table 12: Estimated patient out-of-pocket costs for MBS and PBS itemsMBS & PBS CostsPatient co-paymentYear 1Year 2Year 3Year 4Year 5MBS costs to patientsUnit cost-----DXA Scan - 15% co-payment15.369078592865185730189889284834Vitamin D test - 15% co-payment4.512665627267278782848829099GP visits -assume $140 for 2 x item 2367.4058361118059179094241465305174Total cost to patient (MBS)$175,803$238,191$392,701$459,843$619,106PBS medication costs: AR therapy Annual----0General ordinary patients =36%162.86141022285275432758583472737415General safety net patients =2%1.4612642557387952316611Concessional ordinary =50%36.60316926410997253131122165717Concessional free safety net =12%000000Sub-total-173978351942533890719824909743Adherence rate to AR therapy- 40.5%40.5%40.5%40.5%40.5%Total cost to patient (PBS) AR therapy- $70,461 $142,536 $216,226 $291,529 $368,446 Cost for bone pain and fever2.70$2,338$4,729$7,174$9,673$12,225Total out-of-pocket cost (MBS+PBS)- $248,602 $385,457 $616,101 $761,044 $999,778 AR = anti-resorptives, DXA = dual x-ray absorptiometry, GP = general practitioner, MBS = Medical Benefits Schedule, PBS= Pharmaceutical Benefits Schedule.In summary, over the next five years, the results of the financial estimates were:total eligible patients: 91,366 (includes women continuing treatment)additional costs to MBS for DXA scans: $4.8 milliontotal costs to MBS: $12.2 milliontotal costs to PBS: $1.9 milliontotal costs to other health budgets: savings $0.9 milliontotal costs to consumers for out-of-pocket expenses: $3.0 million.Key issues from ESC for MSACESC noted that the revised analysis indicated that the intervention was less cost-effective than the original analysis; and considered that the populations including those with osteopenia and women from age 50 could no longer be considered cost-effective.ESC recommended that, should MSAC support funding, the proposed item descriptor should be restricted to ‘one service only in a period of 24 consecutive months’ to reflect the new model as indicated in the clinical management algorithm, that is, once every two years.ESC was satisfied with the quality of the revised economic analysis and noted that all issues raised by MSAC had been addressed.Other significant factorsNil.Applicant’s comments on MSAC’s Public Summary DocumentThe Australia and New Zealand Bone and Mineral Society (ANZBMS) highlights that the use of aromatase inhibitors in the treatment of breast cancer is associated with accelerated bone loss and an increased risk of fracture. This loss is analogous to the accelerated bone loss and increased fracture risk observed in men with prostate cancer treated with androgen deprivation therapy, which process is mediated by identical underlying pathophysiology. The MSAC acknowledges that there is some evidence supporting the use of DXA measurement and anti-fracture therapy in women receiving aromatase inhibitor therapy. The MSAC also recognises that under the current rules, only a subset of these women meet the criteria for Medicare-funded DXA measurement, namely those who have had a premature menopause before the age of 45 years, those aged > 70 years and those who have sustained a low trauma fracture. By contrast, all men receiving androgen deprivation therapy are eligible for a Medicare-funded DXA measurements under the male hypogonadism indication. Thus, a gender inequality exists with respect to access to DXA scanning in patients effected by cancer therapy-induced bone loss. The current lack of a PBS indication for antiresorptive therapy to prevent bone loss and fractures due to both aromatase inhibitor and androgen deprivation therapy represents a treatment gap that should be addressed. The MSAC-commissioned economic modelling has indicated that detection and treatment of women with osteoporosis, aged over 60 years, commencing aromatase inhibitor therapy, would be cost-effective with an ICER of approximately $47,000 whereas extending detection and intervention to the population with low bone mass (osteoporosis and osteopenia) would not be cost-effective. ANZBMS would advocate that extending Medicare-funded DXA measurement to women with breast cancer aged 60 years and older, as a logical and appropriate step to begin to address equity and treatment gaps in cancer therapy-induced bone loss and fracture.Further information on MSACMSAC Terms of Reference and other information are available on the MSAC Website at: .au. ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related searches
- colorado department of health and human services
- colorado department of health and environment
- virginia department of health office of licensure
- tennessee department of health and licensure
- texas department of health and human services
- department of health and human services forms
- department of health bureau of vital records
- state of florida department of health license
- florida department of health and vital records
- florida health department of health website
- maine department of health and human services
- colorado department of health and welfare